•
Jun 30, 2021

Natera Q2 2021 Earnings Report

Reported the fastest year-on-year growth quarter as a publicly traded company, expanded market opportunity with positive new data in organ health and oncology, and increased revenue guidance.

Key Takeaways

Natera reported a strong second quarter with a 64.2% increase in total revenue compared to the same period last year. The company processed more tests, achieved higher gross margins, and increased revenue guidance for the year.

Total revenues increased by 64.2% to $142.0 million compared to Q2 2020.

Product revenues increased by 70.7% to $137.2 million compared to Q2 2020.

Approximately 375,700 tests were processed in Q2 2021, compared to 234,100 tests in Q2 2020.

Gross profit increased to $65.9 million, representing a gross margin of 46.4%.

Total Revenue
$142M
Previous year: $86.5M
+64.2%
EPS
-$1.32
Previous year: -$0.75
+76.0%
Tests Processed
375.7K
Previous year: 234.1K
+60.5%
Tests Accessioned
361.5K
Previous year: 221.6K
+63.1%
Total Tests Reported
355.7K
Previous year: 220K
+61.7%
Gross Profit
$65.9M
Previous year: $39.5M
+66.8%
Cash and Equivalents
$581M
Previous year: $571M
+1.6%
Free Cash Flow
-$79.2M
Total Assets
$850M

Natera

Natera

Forward Guidance

Natera anticipates 2021 total revenue of $600 million to $620 million; 2021 gross margin to be approximately 52% to 55% of revenues; selling, general and administrative costs to be approximately $500 million to $520 million; research and development costs to be $220 million to $230 million, and net cash burn to be $300 million to $340 million.